Sign In
Buy IMNM
$22.76
-0.320 (-1.39%)
At Close: Jul 31, 2026
Infinimmune Announces Research Collaboration with Immunome
08:00am, Thursday, 18'th Sep 2025
ALAMEDA, Calif.--(BUSINESS WIRE)-- #antibodies--Infinimmune Announces Research Collaboration with Immunome.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:05pm, Thursday, 04'th Sep 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Wednesday, 03'rd Sep 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome
Immunome: SpringWorks Buyout Informs The Potential Upside Here
10:31pm, Monday, 11'th Aug 2025
Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potent
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
06:45pm, Wednesday, 06'th Aug 2025
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.49 per share a year ago.
Immunome (IMNM) Q2 Revenue Surges 382%
05:32pm, Wednesday, 06'th Aug 2025
Immunome (IMNM -3.59%), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantia
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:51pm, Friday, 01'st Aug 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 03'rd Jul 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
11:31am, Tuesday, 01'st Jul 2025
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 16'th Jun 2025
Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
10:56am, Thursday, 12'th Jun 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the posi
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 05'th Jun 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
11:01am, Monday, 26'th May 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the posi
Immunome to Present at Upcoming Investor Conferences
08:00am, Thursday, 22'nd May 2025
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome to Present at Upcoming Investor Conferences.
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
01:01pm, Tuesday, 13'th May 2025
Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
